<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119873</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 054</org_study_id>
    <secondary_id>10121</secondary_id>
    <nct_id>NCT00119873</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults</brief_title>
  <official_title>A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade, Multivalent Recombinant Adenoviral Vector HIV Vaccine, VRC-HIVADV014-00-VP, in Healthy, HIV-1 Uninfected Adult Participants Who Have Low Titers of Pre-Existing Ad5 Neutralizing Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of and immune response to an&#xD;
      experimental HIV vaccine in HIV uninfected individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HIV epidemic is a major global health challenge. People in developing nations have&#xD;
      limited access to life-sustaining antiretrovirals and account for over 95% of the 5 million&#xD;
      new HIV infections annually. The development of a safe, effective, and widely accessible HIV&#xD;
      vaccine is paramount in these areas. The adenoviral vector vaccine VRC-HIVADV014-00-VP has&#xD;
      been shown to elicit a CD8 cytotoxic lymphocyte (CTL) response believed to be crucial in an&#xD;
      effective preventive HIV vaccine. The purpose of this study is to determine the safety and&#xD;
      immunogenicity of VRC-HIVADV014-00-VP in HIV uninfected adults. In this study, HIV uninfected&#xD;
      individuals with low levels of pre-existing adenovirus neutralizing antibodies will receive&#xD;
      different doses of the preventive vaccine to determine its safety, tolerability, and&#xD;
      immunogenicity.&#xD;
&#xD;
      This study will last 1 year. Participants will be randomly assigned to one of two groups. At&#xD;
      study entry, participants in each group will receive a single injection of either one of two&#xD;
      doses of the adenoviral vector vaccine or placebo. Participants will record their temperature&#xD;
      and other side effects in a symptom log on the day of vaccination and for 3 days thereafter.&#xD;
      Participants will have seven clinic visits over 12 months. A physical exam, HIV and pregnancy&#xD;
      prevention counseling, and blood and urine collection will occur at each visit. Participants&#xD;
      will also be asked about side effects they may be experiencing and medications they are&#xD;
      taking.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood and chemical parameters for 12 months after injection</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Local and systemic adverse reactions for 12 months after injection</measure>
  </primary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVADV014-00-VP</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have access to a participating site and are willing to be followed for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Willing to receive HIV test results&#xD;
&#xD;
          -  Able to understand and comply with study requirements&#xD;
&#xD;
          -  In good general health&#xD;
&#xD;
          -  Have neutralizing adenovirus antibody levels that are less than a 1:12 ratio&#xD;
&#xD;
          -  Agree to use acceptable methods of contraception for at least 21 days prior to study&#xD;
             start and for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  Positive hepatitis B surface antigen&#xD;
&#xD;
          -  Positive anti-hepatitis C virus antibodies&#xD;
&#xD;
          -  Prior receipt of an HIV vaccine&#xD;
&#xD;
          -  Immunosuppressive drugs within 168 days prior to first vaccination&#xD;
&#xD;
          -  Have received donated blood within 120 days prior to first vaccination&#xD;
&#xD;
          -  Have received immunoglobulin within 60 days of the first vaccination&#xD;
&#xD;
          -  Live attenuated vaccines or investigational research agents within 30 days prior to&#xD;
             first vaccination&#xD;
&#xD;
          -  Subunit or killed vaccines within 14 days prior to first vaccination&#xD;
&#xD;
          -  Current preventive or therapeutic anti-tuberculosis (TB) treatment&#xD;
&#xD;
          -  Any medical, psychiatric, or social condition that would interfere with the study&#xD;
&#xD;
          -  Any occupational or other responsibility that would interfere with the study&#xD;
&#xD;
          -  Serious adverse reactions to vaccines&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Immunodeficiency&#xD;
&#xD;
          -  Active syphilis infection. Participants who have been fully treated for syphilis over&#xD;
             6 months prior to study entry are not excluded.&#xD;
&#xD;
          -  Asthma. Participants who have had completely resolved childhood asthma are not&#xD;
             excluded.&#xD;
&#xD;
          -  Diabetes mellitus type I or II. Participants who have had isolated gestational&#xD;
             diabetes are not excluded.&#xD;
&#xD;
          -  Thyroid disease or removal of the thyroid&#xD;
&#xD;
          -  Blood vessel swelling within the last 3 years&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Body mass index (BMI) of 40 or higher&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Cancer. Participants whose cancer has been removed and is unlikely to recur during the&#xD;
             study are not excluded.&#xD;
&#xD;
          -  Seizure disorder. Participants who have not required medication or had a seizure for 3&#xD;
             years prior to study entry are not excluded.&#xD;
&#xD;
          -  Removal of the spleen or have a nonfunctioning spleen&#xD;
&#xD;
          -  Psychiatric conditions that may interfere with the study&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or plan to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Peiperl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Francisco Department of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Vaccine and Prevention CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FHCRC/UW Vaccine CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information on HIV preventive vaccines</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1563</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Shiver J. A non-replicating adenoviral vector as a potential HIV vaccine. Res Initiat Treat Action. 2003 Spring;8(2):14-6.</citation>
    <PMID>12845771</PMID>
  </reference>
  <reference>
    <citation>Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, Chen M, Long R, McKelvey T, Chastain M, Gurunathan S, Tartaglia J, Emini EA, Shiver J. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol. 2004 Oct;78(20):11434-8.</citation>
    <PMID>15452269</PMID>
  </reference>
  <reference>
    <citation>Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med. 2004;55:355-72. Review.</citation>
    <PMID>14746526</PMID>
  </reference>
  <reference>
    <citation>Gómez-Román VR, Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev. 2003 Jul-Sep;5(3):178-85. Review.</citation>
    <PMID>14598567</PMID>
  </reference>
  <results_reference>
    <citation>Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One. 2010 Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579.</citation>
    <PMID>21048953</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2005</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Preventive Vaccine</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>Adenoviridae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

